APA (7th ed.) Citation

SH, L., SY, Y., JH, K., SS, L., AO, K., & JS, L. (2025). Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 Trial". Clinical and molecular hepatology, 31(1), e81. https://doi.org/10.3350/cmh.2024.0829

Chicago Style (17th ed.) Citation

SH, Lee, Yim SY, Kim JH, Lee SS, Kaseb AO, and Lee JS. "Correspondence to Editorial 1 on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial"." Clinical and Molecular Hepatology 31, no. 1 (2025): e81. https://doi.org/10.3350/cmh.2024.0829.

MLA (9th ed.) Citation

SH, Lee, et al. "Correspondence to Editorial 1 on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial"." Clinical and Molecular Hepatology, vol. 31, no. 1, 2025, p. e81, https://doi.org/10.3350/cmh.2024.0829.